newsfilter
← Latest News
GlobeNewswire·

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase